---
title: "This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293928454.md"
description: "Wall Street analysts initiated coverage on five stocks with bullish outlooks. Goldman Sachs rated Neutron Holdings (LIME) Buy with a $39 target. Chardan Capital rated Cipher Digital (CIFR) Buy with a $32 target. Mizuho rated Bending Spoons (BSP) Outperform with a $45 target. Jefferies rated Damora Therapeutics (DMRA) Buy with a $50 target. Stifel rated ITG Buy with a $16 target."
datetime: "2026-07-27T11:56:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293928454.md)
  - [en](https://longbridge.com/en/news/293928454.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293928454.md)
generator: "portal-rs"
---

# This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   Goldman Sachs analyst Eric Sheridan initiated coverage on **Neutron Holdings Inc** (NASDAQ:LIME) with a Buy rating and announced a price target of $39. Neutron Holdings shares closed at $28.23 on Friday. See how other analysts view this stock.
-   Chardan Capital analyst Bill Papanastasiou initiated coverage on **Cipher Digital Inc** (NASDAQ:CIFR) with a Buy rating and announced a price target of $32. Cipher Digital closed at $23.15 on Friday. See how other analysts view this stock.
-   Mizuho analyst Lloyd Walmsley initiated coverage on **Bending Spoons SpA** (NASDAQ:BSP) with an Outperform rating and announced a price target of $45. Bending Spoons shares closed at $34.06 on Friday. See how other analysts view this stock.
-   Jefferies analyst Akash Tewari initiated coverage on **Damora Therapeutics Inc** (NASDAQ:DMRA) with a Buy rating and announced a price target of $50. Damora Therapeutics shares closed at $28.82 on Friday. See how other analysts view this stock.
-   Stifel analyst Brian Brophy initiated coverage on **ITG** (NASDAQ:ITG) with a Buy rating and announced a price target of $16. ITG shares closed at $13.46 on Friday. See how other analysts view this stock.

Considering buying DMRA stock? Here’s what analysts think:

*Photo via Shutterstock*

### Related Stocks

- [ITG.US](https://longbridge.com/en/quote/ITG.US.md)
- [BSP.US](https://longbridge.com/en/quote/BSP.US.md)
- [DMRA.US](https://longbridge.com/en/quote/DMRA.US.md)
- [CIFR.US](https://longbridge.com/en/quote/CIFR.US.md)
- [LIME.US](https://longbridge.com/en/quote/LIME.US.md)
- [CIFU.US](https://longbridge.com/en/quote/CIFU.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy](https://longbridge.com/en/news/295521208.md)
- [Lime withdraws bikes from London borough after complaints from blind residents](https://longbridge.com/en/news/296818764.md)
- [Northern Discovery Metals taps Independent Trading Group as CSE market maker for C$ 5,000 monthly fee](https://longbridge.com/en/news/297368779.md)
- [Vanta Announces Engagement of Independent Trading Group for Market-Making Services to Support Strategic Capital Markets Initiatives | VNTXF Stock News](https://longbridge.com/en/news/297229282.md)
- [Golden Spike hires Independent Trading Group as market maker at CAD 5,500 a month](https://longbridge.com/en/news/297031847.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**